This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin. Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.
This report contains market size and forecasts of Hirudin in global, including the following market information:
Global Hirudin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hirudin Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Hirudin companies in 2021 (%)
The global Hirudin market was valued at 4090.1 million in 2021 and is projected to reach US$ 5018.9 million by 2028, at a CAGR of 3.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Natural Hirudin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hirudin include The Medicines Company, Keyken, Minapharm, Abbott, SALUBRIS, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, DUOPUTAI and Pentapharm. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hirudin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hirudin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hirudin Market Segment Percentages, by Type, 2021 (%)
Natural Hirudin
Recombinant Hirudin
Global Hirudin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hirudin Market Segment Percentages, by Application, 2021 (%)
Thrombosis Disease
Tumor Disease
Others
Global Hirudin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Hirudin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hirudin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hirudin revenues share in global market, 2021 (%)
Key companies Hirudin sales in global market, 2017-2022 (Estimated), (MT)
Key companies Hirudin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
The Medicines Company
Keyken
Minapharm
Abbott
SALUBRIS
Pfizer, Inc
Teva Pharmaceutical Industries Ltd
DUOPUTAI
Pentapharm